Oncology, skin cancer
Relatlimab and nivolumab in untreated and metastatic melanom
In preclinical models, simultaneous inhibition of LAG-3 and PD-1 showed synergistic antitumor activity. This phase
Breast cancer
Pembrolizumab in treatment of triple-negative breast cance
Pembrolizumab in combination with chemotherapy is already FDA-approved for the treatment of patients with triple-negative
Gynecological Cancer
Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide Carcinosarcoma of the Uterus
This phase III study demonstrates that the combination of paclitaxel and carboplatin is non-inferior to
Gynecological Cancer
Levantinib in combination with pembrolizumab in second line treatment the advanced stage endometrial cancer
Phase III data from the 309- KEYNOTE-775 study demonstrate that the combination of levantinib plus
GI Cancer
Codebreak100 evaluates the efficacy of sotorasib in colorectal cancer previously treated with kras p.g12c mutation
Paper recently published in The Lancet Oncology demonstrates that sotorasib may be a therapeutic strategy
Hematology, Oncology
Zuma-5: long-term follow-up demonstrates substantial and sustained benefit of axicabtagene ciloleucel (axi-cel) for iNHL
Axicabtagene ciloleucel is an autologous anti-CD19 CAR T cell therapy indicated for the treatment of
Genitourinary
VISION trial: Radioligand therapy with 177Lu–PSMA-617 for mCRPC
Study shows prolonged imaging-based progression-free survival and overall survival when the radioligand therapy is added
GI: esophagus, Oncology
Prognosis impact of early adjuvant treatment discontinuation in stage III C
A pooled ACCENT/IDEA analysis demonstrates that for patients with stage III colorectal cancer treated with
Oncology
New dimensions of cancer hallmarks
Cancer hallmarks are a tool for understanding the vast complexity of cancer phenotypes and genotypes.
Breast cancer
Neoadjuvant pembrolizumab plus chemotherapy improves event free survival in early TNBC.
Previous data showed that the addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly
GI: esophagus, Oncology
KEYNOTE – 394: Pembrolizumab in second-line treatment of advanced HCC
The phase 3 study, KEYNOTE-394, demonstrated significant benefit of using pembrolizumab in combination with best
GI Cancer
Choice of first line treatment for advanced hepatocellular carcinoma
In this edition of his monthly column, Tiago Biachi, M.D. Advanced Fellow of Gastrointestinal Oncology
GI Cancer
Advanced Esophageal Squamous-Cell Carcinoma gains new treatment options
For decades, despite the poor survival outcomes, the standard treatment for advanced or metastatic esophageal
GI: esophagus, Oncology
Checkmate 9X8 addition the nivolumab in regimen the first -line treatment of metastatic colorectal cancer
Although the primary endpoint of this phase 2 study was not met, the addition of
Gynecological Cancer, Oncology
Cemiplimab shows survival benefit in patients with cervical cancer
Clinical trial EMPOWER-Cervical 1 demonstrates an overall survival benefit of using cemiplimab as monotherapy, compared